國民技術(300077.SZ):與華夏芯公司就高性能微控制器項目開展研發合作
格隆匯6月1日丨國民技術(300077.SZ)公佈,2021年6月1日,公司因芯片項目設計研發所需,與華夏芯(北京)通用處理器技術有限公司(“華夏芯公司”或“關聯方”)就高性能微控制器項目開展研發合作,並就該項目在深圳市南山區簽訂《技術開發合同》,研發設計服務費為2086萬元(含税)。
此次交易系基於公司芯片項目設計研發所需,符合公司實際經營和在微控制器領域的發展戰略規劃,有利於藉助華夏芯公司技術團隊現有的IP及設計經驗,與公司現有的微控制器技術積累形成優勢互補,並通過雙方協力解決項目底層技術難題,從而促進公司在此業務方向的拓展和競爭力,提高收入規模及盈利能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.